Skip to content
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Menu
  • Insights
    • All Insights
    • 2024 Year in Review
    • Pα+ Dashboard
  • Data
    • Psychedelic Company Financing Tracker
    • Psychedelic Drug Development Tracker
    • Worldwide Psychedelic Laws
    • U.S. Psychedelic Policy Reform
    • Psychedelic Patent Trackers
    • Psychedelic Stocks & Companies
  • Advisory
  • Careers
  • Feed
  • Contact
  • Pα+ Content
  • Pα+ Sign in
Subscribe
Search
Close this search box.
Read more about the article Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

  • Post published:December 7, 2021
  • Post category:Press Release
Read more about the article Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to Research DMT and New Analogues to Combat Addiction

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to Research DMT and New Analogues to Combat Addiction

  • Post published:August 26, 2021
  • Post category:Press Release
Read more about the article Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

  • Post published:August 12, 2021
  • Post category:Press Release
Read more about the article Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

  • Post published:July 1, 2021
  • Post category:Press Release
Read more about the article Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

  • Post published:February 25, 2021
  • Post category:Press Release
Read more about the article Jackie von Salm, Co-founder and CSO at Psilera Bioscience

Jackie von Salm, Co-founder and CSO at Psilera Bioscience

  • Post published:December 17, 2020
  • Post category:Interview
Read more about the article Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library

Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library

  • Post published:December 16, 2020
  • Post category:Press Release
Read more about the article Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies

Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies

  • Post published:July 1, 2020
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More